DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts

Access this Article

Search this Article

Author(s)

    • MAKINO Sachio
    • Division of Plastic and Reconstructive Surgery, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences
    • MITSUTAKE Norisato
    • Department of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences
    • NAKASHIMA Masahiro
    • Tissue and Histopathology Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences
    • SAENKO Vladimir A.
    • Department of International Health and Radiation Research, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences
    • OHTSURU Akira
    • Takashi Nagai Memorial International Hibakusha Medical Center, Nagasaki University Hospital
    • UMEZAWA Kazuo
    • Department of Applied Chemistry, Faculty of Science and Technology, Keio University
    • TANAKA Katsumi
    • Division of Plastic and Reconstructive Surgery, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences
    • HIRANO Akiyoshi
    • Division of Plastic and Reconstructive Surgery, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences
    • YAMASHITA Shunichi
    • Department of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences

Abstract

Background:Keloid is a benign dermal tumor characterized by proliferation of dermal fibroblasts and overproduction of extracellular matrix (ECM). Nuclear factor kappaB (NF-κB) plays an important role in regulation of inflammation, immune response and cell proliferation. Activation of the NF-κB pathway is thought to be closely linked to abnormal cell proliferation and ECM production in keloid fibroblasts. Objective:This study was set out to investigate the effects of a novel selective NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on keloid fibroblasts. Methods:Primary normal and keloid dermal fibroblasts were used for this study. NF-κB activity was assessed by DNA-binding assay and immunohistochemistry. The effect of DHMEQ was evaluated by cell viability, cell growth and type I collagen accumulation. Results:Basal NF-κB activity was constitutively elevated in keloid fibroblasts, indicating that this pathway is involved in keloid pathogenesis. DHMEQ markedly reduced cell proliferation and type I collagen accumulation in keloid fibroblasts. Conclusion:The inhibition of NF-κB by DHMEQ may be an attractive therapeutic approach for keloids.

Journal

  • Journal of dermatological science

    Journal of dermatological science 51(3), 171-180, 2008-09-01

References:  36

Codes

  • NII Article ID (NAID)
    10024298393
  • NII NACSIS-CAT ID (NCID)
    AA1075636X
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    09231811
  • Data Source
    CJP  IR 
Page Top